Latigo Biotherapeutics, a Thousand Oaks, CA-based clinical-stage biotechnology firm growing non-opioid ache medicines that concentrate on ache at its supply, raised $135M in Collection A funding.
Westlake Village BioPartners incubated the corporate and led the spherical with 5AM Ventures and Foresite Capital as co-leads with participation from Nook Ventures. The corporate has appointed Desmond Padhi, Pharm.D., working associate at Westlake as interim chief government officer (CEO) and Nancy Stagliano, Ph.D., CEO of Neuron23, Inc., as chair of the board.
The corporate intends to make use of the funds to help the continued development of its portfolio of novel ache therapeutics.
Led by CEO Desmond Padhi, Latigo Biotherapeutics is a clinical-stage biotechnology firm growing non-opioid ache medicines that concentrate on the basic mechanism of ache transduction. Its proprietary, in-house know-how generates novel medicine towards targets validated by human genetics utilizing probably the most superior synthetic intelligence, machine studying, structure-based, and knowledge-based design methods to optimize efficiency and selectivity.
Latigo’s lead program, LTG-001, is an oral, selective Nav1.8 inhibitor at the moment in a Part 1 medical trial in wholesome volunteers and supposed to deal with acute and persistent ache. LTG-001 has the potential to be best-in-class with a speedy onset, significant efficacy, and superior security to plain of care with no central nervous system results. Along with LTG-001, the corporate has a set of Nav1.8 inhibitors, enabling Latigo to deal with the broad potential of such a goal within the clinic. Past Nav1.8, the corporate has a pipeline of novel, genetically recognized targets with small molecule applications on the discovery stage.
FinSMEs
14/02/2024
